OLDER peopleRESPIRATORY syncytial virus infection vaccinesRESPIRATORY syncytial virusVACCINE effectivenessVIRAL vaccinesThis study evaluates the effectiveness of the respiratory syncytial virus vaccine against hospitalization for acute respiratory illness among US adults aged 60 years and older....
In short, the new guidelines encourage all adults ages 75 and older and individuals who are between 60 and 74 with an elevated risk of getting severe RSV to get the RSV vaccine. For adults between 60 and 74 years, an elevated risk of severe RSV may be a result of a c...
There's no approved vaccine for RSV, or respiratory syncytial virus, which can be more severe in older adults as well as in very young children. Moderna isn't the only vaccine-maker on the trail of the sought-after vaccine, however: GlaxoSmithKline, Johnson & Johnson and Pfizer all haveva...
/ -- Today, the U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use inthe United States. Arexvy is approved for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and ol...
The vaccines should be administered using shared clinical decision-making, meaning individuals can receive a single dose of the vaccine based on conversations with their health care provider about whether RSV vaccination is the best course of action for them. CDC Director Rochelle P Walensky, MD, ...
as well as the potential side effects associated with the RSV vaccine for adults 60 and older. For rural and frontier residents, she said, their biggest barriers to getting vaccinations are access to shots and transportation to a health clinic to receive them, on ...
The first vaccine against respiratory syncytial virus (RSV) has been approved by the US Food and Drug Administration. The vaccine, named Arexvy, will be given to people 60 years and older.
The first vaccine for respiratory syncytial virus (RSV) has been approved by the U.S. Food and Drug Administration for use in seniors aged 60 and older.
In the US, Arexvy is indicated for the prevention of RSV-LRTD in individuals 60 years of age and older. GSK’s RSV older adult vaccine is not currently approved anywhere outside the US. The proposed trade name remains subject to regulatory approval out...
In an international study of about 25,000 people 60 and older, one dose of the vaccine was nearly 83% effective at preventing RSV lung infections, and reduced the risk of severe infections by 94%. To see how long protection lasts, GSK is tracking study participants for three years, compari...